Atea Pharmaceuticals Q4 2023 GAAP EPS $(0.47) Beats $(0.51) Estimate
Portfolio Pulse from Benzinga Newsdesk
Atea Pharmaceuticals (NASDAQ:AVIR) reported Q4 2023 GAAP EPS losses of $(0.47), surpassing the analyst consensus estimate of $(0.51) by 7.84%. However, this represents a 14.63% increase in losses compared to $(0.41) per share from the same period last year.
February 28, 2024 | 9:31 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Atea Pharmaceuticals reported a smaller-than-expected loss per share for Q4 2023, but with an increase in losses year-over-year.
Beating the EPS estimate could be seen positively by investors, indicating better-than-expected financial performance. However, the increase in losses year-over-year might raise concerns about the company's profitability and growth trajectory, potentially balancing out the positive impact of the earnings beat.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100